In 201 consecutive patients biopsied for suspected NASH, liver damage has been quantified by NAFLD activity score, circulating PCSK9 by ELISA, and hepatic mRNA by qRT–PCR in 76 of the patients. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatohepatitis.